Aviva PLC cut its holdings in shares of Teleflex Incorporated (NYSE:TFX) by 3.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 21,990 shares of the medical technology company’s stock after selling 700 shares during the period. Aviva PLC’s holdings in Teleflex were worth $5,851,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of TFX. FMR LLC grew its position in shares of Teleflex by 632.5% during the 3rd quarter. FMR LLC now owns 1,343,305 shares of the medical technology company’s stock valued at $357,440,000 after acquiring an additional 1,159,914 shares during the period. Bessemer Group Inc. grew its position in shares of Teleflex by 5,322.9% during the 3rd quarter. Bessemer Group Inc. now owns 407,799 shares of the medical technology company’s stock valued at $108,511,000 after acquiring an additional 400,279 shares during the period. Atlanta Capital Management Co. L L C grew its position in shares of Teleflex by 17.7% during the 3rd quarter. Atlanta Capital Management Co. L L C now owns 2,650,228 shares of the medical technology company’s stock valued at $705,199,000 after acquiring an additional 399,301 shares during the period. Marshall Wace LLP grew its position in shares of Teleflex by 1,177.7% during the 2nd quarter. Marshall Wace LLP now owns 342,631 shares of the medical technology company’s stock valued at $91,897,000 after acquiring an additional 315,814 shares during the period. Finally, Jennison Associates LLC acquired a new stake in shares of Teleflex during the 2nd quarter valued at about $60,706,000. Hedge funds and other institutional investors own 92.42% of the company’s stock.
TFX stock opened at $256.64 on Friday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.51 and a current ratio of 2.26. Teleflex Incorporated has a 12-month low of $227.52 and a 12-month high of $288.78. The stock has a market capitalization of $12.24 billion, a P/E ratio of 30.55, a PEG ratio of 2.15 and a beta of 1.14.
Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, November 1st. The medical technology company reported $2.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.41 by $0.11. Teleflex had a return on equity of 18.04% and a net margin of 2.81%. The company had revenue of $609.70 million for the quarter, compared to analysts’ expectations of $609.05 million. During the same period in the previous year, the firm posted $2.12 EPS. Teleflex’s revenue was up 14.0% compared to the same quarter last year. As a group, analysts expect that Teleflex Incorporated will post 9.91 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 14th. Investors of record on Thursday, November 15th will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 0.53%. The ex-dividend date of this dividend is Wednesday, November 14th. Teleflex’s payout ratio is 16.19%.
In related news, insider Thomas E. Powell sold 5,200 shares of Teleflex stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $269.64, for a total value of $1,402,128.00. Following the sale, the insider now directly owns 12,432 shares in the company, valued at approximately $3,352,164.48. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Thomas Anthony Kennedy sold 20,635 shares of Teleflex stock in a transaction dated Wednesday, September 19th. The stock was sold at an average price of $268.91, for a total value of $5,548,957.85. Following the completion of the sale, the vice president now owns 6,046 shares in the company, valued at $1,625,829.86. The disclosure for this sale can be found here. Over the last quarter, insiders sold 82,329 shares of company stock worth $21,275,053. 2.56% of the stock is currently owned by insiders.
A number of equities research analysts have recently commented on the company. Needham & Company LLC restated a “buy” rating and set a $315.00 target price on shares of Teleflex in a research report on Friday, November 2nd. Barclays assumed coverage on Teleflex in a research report on Monday, October 15th. They set an “equal weight” rating and a $266.00 target price on the stock. UBS Group assumed coverage on Teleflex in a research report on Tuesday, November 27th. They set a “buy” rating and a $310.00 target price on the stock. TheStreet upgraded Teleflex from a “c+” rating to a “b-” rating in a research report on Wednesday, November 28th. Finally, Piper Jaffray Companies raised their target price on Teleflex to $310.00 and gave the company an “overweight” rating in a research report on Friday, November 2nd. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Teleflex presently has an average rating of “Buy” and a consensus price target of $291.67.
COPYRIGHT VIOLATION NOTICE: “Aviva PLC Has $5.85 Million Stake in Teleflex Incorporated (TFX)” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/12/08/aviva-plc-has-5-85-million-stake-in-teleflex-incorporated-tfx.html.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Recommended Story: Analyst Ratings
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.